Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    Ballia: In an alleged case of medical negligence, a case has been registered against five doctors at a private hospital in Ballia, Uttar Pradesh, following the death of a 24-year-old…

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    The yoga guru, who was arrested last week, misled people in the name of faith and Ayurveda, said investigators. Surat: Just days after Ahmedabad cops dismantled a massive fake currency…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    24-year-old woman dies during surgery; Five UP doctors booked for negligence

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    Extortion, Fake Medicines: The Fall Of Surat’s Yoga Guru

    Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

    Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

    Ship of Domestic Medical Device Industry flounders, thanks to Israel-Iran War

    Ship of Domestic Medical Device Industry flounders, thanks to Israel-Iran War

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    DCGI Cracks Down On 90 Unapproved Fixed-Dose Combinations: Cough Syrups, Vitamins, Diabetes Drugs Among Those Flagged For Sale Without Central Approval

    India’s drug body flags 90 unapproved FDC medicines, states told to take action

    India’s drug body flags 90 unapproved FDC medicines, states told to take action